Area of research
Oncology · Pharmacology
Research interest
Research interests include Drug Transport and Resistance Mechanisms, Pharmacogenetics and Drug Metabolism, Pharmacological Effects and Toxicity Studies, and Analytical Methods in Pharmaceuticals.
Mathematical Modeling in Drug Metabolism and Pharmacokinetics: Correct In Vitro, Not Always Valid In Vivo
Application of Kirchhoff’s Laws to pharmacologic and pharmacokinetic analyses
Response to the commentary on “are all measures of liver Kpuu a function of FH, as determined following oral dosing, or have we made a critical error in defining hepatic drug clearance?”
Net Influx Rather Than Directional Rates: Re-evaluating Transporter Characterization In Vivo and In Vitro for Renal and Hepatic Clearance
An Explanation of Why Dose-Corrected Area Under the Curve for Alternate Administration Routes Can Be Greater than for Intravenous Dosing
Commentary: Pharmacokinetic Theory Must Consider Published Experimental Data
Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?
The Uses and Advantages of Kirchhoff’s Laws vs. Differential Equations in Pharmacology, Pharmacokinetics, and (Even) Chemistry
Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential
State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References
State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References
Using an animal model to predict the effective human dose for oral multiple sclerosis drugs
Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization
Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization
There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions
Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption
Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans
Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies
Using Individualized Patient Data for Prediction of Population Dosing Recommendations Versus Predictions of Individualized Patient Dosing
The Critical Role of Passive Permeability in Designing Successful Drugs
The Critical Role of Passive Permeability in Designing Successful Drugs.
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis
Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?
Investigating the Theoretical Basis for In Vitro–In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways
Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition
Volume of Distribution is Unaffected by Metabolic Drug–Drug Interactions
The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions
Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System
In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction
The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation